Skip to main content

Key Product Details

Validated by

Knockout/Knockdown, Independent Antibodies

Species Reactivity

Validated:

Human

Applications

Chromatin Immunoprecipitation (ChIP), Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Knockdown Validated, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

1.0 mg/ml

Product Summary for Senataxin Antibody

Immunogen

The immunogen recognized by this antibody maps to a region between residue 875 and 925 of human senataxin using the numbering given in entry NP_055861.2 (GeneID 23064).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

303 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for Senataxin Antibody

Western Blot: Senataxin Antibody [NB100-57542] - Whole cell lysate (5 ug) from HeLa, 293T, Jurkat, and A549 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Senataxin antibody used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 75 seconds.
Immunoprecipitation: Senataxin Antibody [NB100-57542] - Detection of human Senataxin by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Senataxin antibody NB100-57542 used for IP at 3 ug per reaction. Senataxin was also immunoprecipitated by rabbit anti-Senataxin antibody NB100-57543. For blotting immunoprecipitated Senataxin, NB100-57542 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.
Knockdown Validated: Senataxin Antibody [NB100-57542] - SAN1 interacts with the RNA/DNA helicase sSenataxin. IB of SETX siRNA knockdown. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/s41467-018-05008-8), licensed under a CC-BY license.

Applications for Senataxin Antibody

Application
Recommended Usage

Immunoprecipitation

2 - 5 ug/mg lysate

Western Blot

1:2000-1:10000
Application Notes
Use in ICC/IF reported in scientific literature (PMID: 24105744). Use in chromatin immunoprecipitation reported in scientific literature (PMID: 31533039).
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 2 reviews rated 3 using NB100-57542 in the following applications:

Published Applications

Read 8 publications using NB100-57542 in the following applications:

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Preservative

0.09% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: Senataxin

Mutations in Senataxin result in the neurodegenerative disorders Ataxia-Oculomotor Apraxia 2 (AOA2) and amyotrophic lateral sclerosis (ALS4). Senataxin bears an RNA/DNA helicase domain suggesting a role in DNA and RNA processing and has recently been found to be involved in the DNA damage response. Alternate names for Senataxin include SEN1 homolog, SETX, ALS4, KIAA0625, SCAR1, and AOA2.

Alternate Names

ALS4recessive, non-Friedreich type 1, AOA2FLJ43459, DKFZp781B151, KIAA0625FLJ12840, senataxin, SETX

Entrez Gene IDs

23064 (Human)

Gene Symbol

SETX

UniProt

Additional Senataxin Products

Product Documents for Senataxin Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Senataxin Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...